Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 7/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1906153 | 0.87 | SIRT2 (0.63) | SIRT2KIF11 | |
| SCHEMBL330276 | 0.85 | SIRT2 (0.52) | SIRT2MEN1KMT2ATDP1KIF11 | |
| SCHEMBL11370850 | 0.77 | MEN1 (0.70) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL14962372 | 0.76 | SIRT2 (0.52) | SIRT2KIF11 | |
| SCHEMBL20043060 | 0.76 | SIRT2 (0.52) | SIRT2KIF11GAA | |
| SCHEMBL25491030 | 0.76 | KMT2A (0.52) | SIRT2MEN1KMT2ATDP1MAOA | |
| SCHEMBL7206096 | 0.76 | KIF11 (0.57) | SIRT2KIF11 | |
| SCHEMBL11490946 | 0.75 | KIF11 (0.52) | SIRT2KIF11 | |
| SCHEMBL17345974 | 0.73 | SIRT2 (0.50) | SIRT2KIF11 | |
| SCHEMBL19154882 | 0.73 | SIRT2 (0.50) | SIRT2KIF11SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207893-A1 | NOVEL CALCIUM MODULATORS | MYOTHERIX, INC. | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207893-A1 | NOVEL CALCIUM MODULATORS | CACNA1E, CASR, CACNA1D | SIRT2 2911/4885MEN1 1397/4885KMT2A 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.